Zogenix Inc. (ZGNX)
26.68
0.00 (0.00%)
Apr 24, 2025, 3:47 PM - Market open
0.00% (1D)
| Bid | n/a |
| Market Cap | 0 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 11,252,392 |
| Avg. Volume (20D) | 3,098,164 |
| Open | 26.60 |
| Previous Close | 26.68 |
| Day's Range | 26.51 - 26.90 |
| 52-Week Range | 11.03 - 26.90 |
| Beta | 0.90 |
About ZGNX
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in P...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 23, 2010
Employees 327
Stock Exchange NASDAQ
Ticker Symbol ZGNX
Website https://www.zogenix.com